2022
RACIAL-ETHNIC VARIATION IN MULTIMORBIDITY PATTERNS AND HEALTHCARE SERVICES AMONG OLDEST-OLD PATIENTS
Cho J, Rahimighazikalayeh G, Allore H. RACIAL-ETHNIC VARIATION IN MULTIMORBIDITY PATTERNS AND HEALTHCARE SERVICES AMONG OLDEST-OLD PATIENTS. Innovation In Aging 2022, 6: 795-795. PMCID: PMC9767161, DOI: 10.1093/geroni/igac059.2870.Peer-Reviewed Original ResearchMultiple chronic conditionsOldest-old patientsHealthcare service utilizationPatterns of multimorbidityClinic visitsEmergency departmentHispanic patientsService utilizationHealthcare systemAge-related risk factorsIntegrated healthcare systemRacial-ethnic variationsMetabolism syndromeWhite patientsBlack patientsMultimorbidity patternsChronic conditionsRisk factorsClinical dataPatientsCare managementAlzheimer's diseaseDiverse patientsRelated dementiaSignificant association
2016
Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions
Allore HG, Zhan Y, Cohen AB, Tinetti ME, Trentalange M, McAvay G. Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions. The Journals Of Gerontology Series A 2016, 71: 1113-1116. PMID: 26748093, PMCID: PMC4945884, DOI: 10.1093/gerona/glv223.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCardiovascular DiseasesDrug PrescriptionsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMedicareMultiple Chronic ConditionsPractice Guidelines as TopicRetrospective StudiesSurveys and QuestionnairesSurvival RateThiazidesTreatment OutcomeUnited StatesConceptsMultiple chronic conditionsAverage attributable fractionChronic conditionsAttributable fractionCardiovascular conditionsHeart failureMedicare Current Beneficiary Survey participantsRenin-angiotensin system blockersGuideline-recommended medicationsMore chronic conditionsAge-stratified modelsSystem blockersBeta blockersCardiovascular medicationsOral medicationsAtrial fibrillationMedication effectsMedicationsAge strataParticipant characteristicsOlder adultsSurvivalThiazidesBlockersAgeIndividualized Absolute Risk Calculations for Persons with Multiple Chronic Conditions: Embracing Heterogeneity, Causality, and Competing Events
Allore H, McAvay G, Fragoso C, Murphy TE. Individualized Absolute Risk Calculations for Persons with Multiple Chronic Conditions: Embracing Heterogeneity, Causality, and Competing Events. International Journal Of Statistics In Medical Research 2016, 5: 48-55. PMID: 27076862, PMCID: PMC4827855, DOI: 10.6000/1929-6029.2016.05.01.5.Peer-Reviewed Original ResearchMultiple chronic conditionsPatient-centered outcomesPatient reported outcomesAbsolute risk calculationRisk calculatorChronic conditionsMore chronic medical conditionsPopulation of patientsChronic medical conditionsComplex treatment decisionsTreatment effectsPatient characteristicsAbsolute riskReported outcomesTreatment decisionsMedical conditionsPropensity score methodsSpecific treatmentRisk calculationOutcomesCompeting EventsPatientsTreatmentRiskScore method
2015
Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study
Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. The BMJ 2015, 351: h4984. PMID: 26432468, PMCID: PMC4591503, DOI: 10.1136/bmj.h4984.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsMultiple chronic conditionsSelective serotonin reuptake inhibitorsAdjusted hazard ratioRisk of deathCalcium channel blockersChronic conditionsHazard ratioΒ-blockersCohort studyReuptake inhibitorsAtrial fibrillationOlder adultsChannel blockersCardiovascular drugsSSRIs/serotonin-norepinephrine reuptake inhibitorsRenin-angiotensin system blockersNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCommon combinationRAS blockersSystem blockersStudy drugHeart failureThromboembolic disease